Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:41:43.102Z.
Consensus retrieved: 2026-10-06T10:23:03.597Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:41:43.102Z.
Quote observation: 2026-10-06T16:40:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c88c4f39e0f2b8ce509c05ad310ef4a925915372bb385716b1b31bbca6f45484
Forward PE Ratio (N/A) = Dated Quote Price ($0.32) / Consensus Forward EPS ($-0.46)
FORWARD PE RATIO
N/A
Context Therapeutics Inc.
Market Cap
$29.41M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Context Therapeutics Inc. (CNTX) | $29.41M | N/A |
| Quantum Cyber N.V. (QUCY)vs › | $29.60M | N/A |
| OneMedNet Corporation (ONMD)vs › | $29.10M | N/A |
| BeyondSpring Inc. (BYSI)vs › | $29.96M | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $30.02M | N/A |
| CervoMed Inc. (CRVO)vs › | $30.23M | N/A |
| MDxHealth S.A. (MDXH)vs › | $30.40M | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.24M | N/A |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $30.69M | N/A |
| InspireMD, Inc. (NSPR)vs › | $28.10M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.32, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.46 | $-0.53 – $-0.40 | 7 | n/m |
| 2027-12-31 | $-0.43 | $-0.46 – $-0.39 | 6 | n/m |
| 2028-12-31 | $-0.55 | $-0.70 – $-0.42 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
